Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of vildagliptin add-on therapy in type 2 diabetes mellitus
jRCT2080221153Phase 3
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novartis. Primary endpoint: Primary safety outcomes.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221153.